Tectonic Therapeutic (TECX) CMO receives RSU and stock option awards

Rhea-AI Filing Summary

Ruddy Marcella K. reported acquisition or exercise transactions in this Form 4 filing.

Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy reported equity awards on March 4, 2026. She received 26,500 shares of common stock in the form of restricted stock units that vest in three equal annual installments on March 4, 2027, 2028 and 2029, subject to continued service. She was also granted an option for 24,250 shares, vesting in 48 equal monthly installments beginning April 4, 2026. Following these awards, her directly held common stock totaled 79,747 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ruddy Marcella K.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	24,250	$0.00	--
Grant/Award	Common Stock	26,500	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 24,250 shares (Direct); Common Stock — 79,747 shares (Direct)

Footnotes (1)

1. These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ruddy Marcella K.

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		26,500(1)	A	$0	79,747	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$27.41	03/04/2026		A		24,250		(2)	03/03/2036	Common Stock	24,250	$0	24,250	D

Explanation of Responses:

1. These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Daniel Lochner, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TECX Chief Medical Officer Marcella K. Ruddy report?

Marcella K. Ruddy reported equity awards consisting of restricted stock units and stock options from Tectonic Therapeutic. She received 26,500 common shares via restricted stock units and an option covering 24,250 shares, both subject to multi-year vesting conditions tied to her continued service with the company.

How many TECX restricted stock unit shares were granted to the Chief Medical Officer?

The Chief Medical Officer received 26,500 shares of Tectonic Therapeutic common stock in the form of restricted stock units. These units convert into shares over time, vesting in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, contingent on continued service.

What are the vesting terms for Marcella K. Ruddy’s TECX restricted stock units?

Her restricted stock units vest in three equal annual installments. The vesting dates are March 4, 2027, March 4, 2028, and March 4, 2029. Each installment requires that she remain in continued service with Tectonic Therapeutic through the applicable vesting date.

What stock option grant did the TECX Chief Medical Officer receive?

She received an employee stock option covering 24,250 shares of Tectonic Therapeutic common stock. The option vests in 48 equal monthly installments beginning on April 4, 2026, with each monthly vesting conditioned on her continued service to the company on that date.

How many TECX common shares does the Chief Medical Officer hold after these transactions?

After the reported award of restricted stock units, the Chief Medical Officer’s directly held common stock position is 79,747 shares. This figure reflects her beneficial ownership following the March 4, 2026 equity grants as disclosed in the Form 4 insider transaction report.

Do Marcella K. Ruddy’s TECX equity awards involve any purchase or sale of shares?

The reported transactions are classified as grants or awards, not open-market purchases or sales. Both the 26,500 restricted stock units and the 24,250-share stock option were acquired as compensation awards, with a reported transaction price per share of $0.0000 in the filing.